134 related articles for article (PubMed ID: 18818704)
1. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.
Dijkstra MK; van Lom K; Tielemans D; Elstrodt F; Langerak AW; van 't Veer MB; Jongen-Lavrencic M
Leukemia; 2009 Mar; 23(3):625-7. PubMed ID: 18818704
[No Abstract] [Full Text] [Related]
2. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
3. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
[TBL] [Abstract][Full Text] [Related]
4. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
Fabbri M; Bottoni A; Shimizu M; Spizzo R; Nicoloso MS; Rossi S; Barbarotto E; Cimmino A; Adair B; Wojcik SE; Valeri N; Calore F; Sampath D; Fanini F; Vannini I; Musuraca G; Dell'Aquila M; Alder H; Davuluri RV; Rassenti LZ; Negrini M; Nakamura T; Amadori D; Kay NE; Rai KR; Keating MJ; Kipps TJ; Calin GA; Croce CM
JAMA; 2011 Jan; 305(1):59-67. PubMed ID: 21205967
[TBL] [Abstract][Full Text] [Related]
5. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.
Lin K; Farahani M; Yang Y; Johnson GG; Oates M; Atherton M; Douglas A; Kalakonda N; Pettitt AR
Br J Haematol; 2014 Nov; 167(3):346-55. PubMed ID: 25040181
[TBL] [Abstract][Full Text] [Related]
6. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
7. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
[TBL] [Abstract][Full Text] [Related]
8. Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia.
Fink SR; Smoley SA; Stockero KJ; Paternoster SF; Thorland EC; Van Dyke DL; Shanafelt TD; Zent CS; Call TG; Kay NE; Dewald GW
Cancer Genet Cytogenet; 2006 Jun; 167(2):177-81. PubMed ID: 16737921
[TBL] [Abstract][Full Text] [Related]
9. Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
Joshi AD; Dickinson JD; Hegde GV; Sanger WG; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
Cancer Genet Cytogenet; 2007 Jan; 172(2):120-6. PubMed ID: 17213020
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
[TBL] [Abstract][Full Text] [Related]
12. p53 protein expression in chronic lymphocytic leukemia.
Sellmann L; Carpinteiro A; Nückel H; Scholtysik R; Siemer D; Klein-Hipass L; Kube D; Dürig J; Dührsen U; Stanelle J; Küppers R
Leuk Lymphoma; 2012 Jul; 53(7):1282-8. PubMed ID: 22220854
[TBL] [Abstract][Full Text] [Related]
13. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?
Marinelli M; Raponi S; Del Giudice I; De Propris MS; Nanni M; Intoppa S; Milani ML; Mauro FR; Guarini A; Foà R
Am J Clin Pathol; 2011 Jan; 135(1):173-4. PubMed ID: 21173142
[No Abstract] [Full Text] [Related]
14. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
[TBL] [Abstract][Full Text] [Related]
15. [Molecular cytogenetic characteristics of chronic lymphocytic leukemia].
Xu W; Li JY; Pan JL; Qiu HR; Shen YF; Xiao B; Chen LJ; Wu YF; Sheng RL; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):349-52. PubMed ID: 17044998
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
[TBL] [Abstract][Full Text] [Related]
17. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
[TBL] [Abstract][Full Text] [Related]
18. Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes.
Kalla C; Nentwich H; Schlotter M; Mertens D; Wildenberger K; Döhner H; Stilgenbauer S; Lichter P
Genes Chromosomes Cancer; 2005 Feb; 42(2):128-43. PubMed ID: 15543602
[TBL] [Abstract][Full Text] [Related]
19. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.
Dickinson JD; Joshi A; Iqbal J; Sanger W; Bierman PJ; Joshi SS
Int J Mol Med; 2006 May; 17(5):769-78. PubMed ID: 16596259
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).
Dong HJ; Zhou LT; Zhu DX; Wang DM; Fang C; Zhu HY; Zhuang Y; Miao KR; Xu W; Li JY
Ann Hematol; 2011 Jun; 90(6):709-17. PubMed ID: 21113594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
